118 related articles for article (PubMed ID: 17551143)
1. Preliminary breast cancer vaccine study shows promise.
Bankhead C
J Natl Cancer Inst; 2007 Jun; 99(11):836. PubMed ID: 17551143
[No Abstract] [Full Text] [Related]
2. Phase I trial of novel HER-2 vaccine for breast cancer initiated.
Expert Rev Anticancer Ther; 2002 Oct; 2(5):483. PubMed ID: 12382513
[No Abstract] [Full Text] [Related]
3. Breast cancer vaccines: current research and future prospects.
Cameron DA
Expert Rev Vaccines; 2002 Jun; 1(1):29-34. PubMed ID: 12908510
[TBL] [Abstract][Full Text] [Related]
4. Combined clinical trial results of a HER2/neu (E75) vaccine for the prevention of recurrence in high-risk breast cancer patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02.
Peoples GE; Holmes JP; Hueman MT; Mittendorf EA; Amin A; Khoo S; Dehqanzada ZA; Gurney JM; Woll MM; Ryan GB; Storrer CE; Craig D; Ioannides CG; Ponniah S
Clin Cancer Res; 2008 Feb; 14(3):797-803. PubMed ID: 18245541
[TBL] [Abstract][Full Text] [Related]
5. Comparison of different HER2/neu vaccines in adjuvant breast cancer trials: implications for dosing of peptide vaccines.
Benavides LC; Sears AK; Gates JD; Clifton GT; Clive KS; Carmichael MG; Holmes JP; Mittendorf EA; Ponniah S; Peoples GE
Expert Rev Vaccines; 2011 Feb; 10(2):201-10. PubMed ID: 21332269
[TBL] [Abstract][Full Text] [Related]
6. Breast cancer vaccines: promise for the future or pipe dream?
Mittendorf EA; Peoples GE; Singletary SE
Cancer; 2007 Oct; 110(8):1677-86. PubMed ID: 17763371
[TBL] [Abstract][Full Text] [Related]
7. Biological therapies for breast carcinoma: concepts for improvement in survival.
Borden EC; Esserman L; Linder DJ; Campbell MJ; Fulton AM
Semin Oncol; 1999 Aug; 26(4 Suppl 12):28-40. PubMed ID: 10482192
[TBL] [Abstract][Full Text] [Related]
8. HER2 vaccination in high-risk breast cancer.
Peoples GE
Clin Adv Hematol Oncol; 2009 Nov; 7(11):715-7. PubMed ID: 20075829
[No Abstract] [Full Text] [Related]
9. Results of the first phase I clinical trial of the novel II-key hybrid preventive HER-2/neu peptide (AE37) vaccine.
Holmes JP; Benavides LC; Gates JD; Carmichael MG; Hueman MT; Mittendorf EA; Murray JL; Amin A; Craig D; von Hofe E; Ponniah S; Peoples GE
J Clin Oncol; 2008 Jul; 26(20):3426-33. PubMed ID: 18612158
[TBL] [Abstract][Full Text] [Related]
10. Perspectives on the development of a therapeutic HER-2 cancer vaccine.
Renard V; Leach DR
Vaccine; 2007 Sep; 25 Suppl 2():B17-23. PubMed ID: 17630057
[TBL] [Abstract][Full Text] [Related]
11. Cancer vaccines: the role of tumor burden in tipping the scale toward vaccine efficacy.
Salazar LG; Disis ML
J Clin Oncol; 2005 Oct; 23(30):7397-8. PubMed ID: 16186591
[No Abstract] [Full Text] [Related]
12. Common adjuvant breast cancer therapies do not inhibit cancer vaccine induced T cell immunity.
Coveler AL; Goodell V; Webster DJ; Salazar LG; Fintak PA; Childs JS; Higgins DM; Disis ML
Breast Cancer Res Treat; 2009 Jan; 113(1):95-100. PubMed ID: 18236151
[TBL] [Abstract][Full Text] [Related]
13. Vaccine immunotherapy in breast cancer treatment: promising, but still early.
Curigliano G; Spitaleri G; Dettori M; Locatelli M; Scarano E; Goldhirsch A
Expert Rev Anticancer Ther; 2007 Sep; 7(9):1225-41. PubMed ID: 17892423
[TBL] [Abstract][Full Text] [Related]
14. Immunization of high-risk breast cancer patients with clustered sTn-KLH conjugate plus the immunologic adjuvant QS-21.
Gilewski TA; Ragupathi G; Dickler M; Powell S; Bhuta S; Panageas K; Koganty RR; Chin-Eng J; Hudis C; Norton L; Houghton AN; Livingston PO
Clin Cancer Res; 2007 May; 13(10):2977-85. PubMed ID: 17504999
[TBL] [Abstract][Full Text] [Related]
15. Vaccines: an innovative approach to treating cancer.
Pazdur MP; Jones JL
J Infus Nurs; 2007; 30(3):173-8. PubMed ID: 17505219
[TBL] [Abstract][Full Text] [Related]
16. Predicted B-cell epitopes of HER-2 oncoprotein by a bioinformatics method: a clue for breast cancer vaccine development.
Wiwanitkit V
Asian Pac J Cancer Prev; 2007; 8(1):137-8. PubMed ID: 17477789
[TBL] [Abstract][Full Text] [Related]
17. Positive Phase II interim data on AE37 cancer vaccine released.
Hum Vaccin Immunother; 2012 Feb; 8(2):152. PubMed ID: 22426363
[No Abstract] [Full Text] [Related]
18. New peptide vaccine for HER2-expressing breast tumors.
Rochman S
J Natl Cancer Inst; 2015 Feb; 107(2):. PubMed ID: 25677037
[No Abstract] [Full Text] [Related]
19. Treatment with autologous antigen-presenting cells activated with the HER-2 based antigen Lapuleucel-T: results of a phase I study in immunologic and clinical activity in HER-2 overexpressing breast cancer.
Park JW; Melisko ME; Esserman LJ; Jones LA; Wollan JB; Sims R
J Clin Oncol; 2007 Aug; 25(24):3680-7. PubMed ID: 17704416
[TBL] [Abstract][Full Text] [Related]
20. HER2-Based Immunotherapy for Breast Cancer.
Cui N; Shi J; Yang C
Cancer Biother Radiopharm; 2018 Jun; 33(5):169-175. PubMed ID: 29874101
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
